The blood-brain barrier controls the exchange of substances between the blood and the brain. It protects the brain from toxins and pathogens, but at the same time it can make the delivery of therapeutic agents to the brain more difficult.
BioArctic is developing technology that facilitates the passage of antibodies across the blood-brain barrier. Together with Uppsala University, BioArctic received research grants during 2019 from Sweden’s Innovation Agency, Vinnova, for continued research in the blood-brain barrier project.
The research, which is at an early stage, has shown highly encouraging results and the technology has significant potential in the treatment of several different diseases of the brain.
The project is owned by BioArctic.